Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick M Sluss

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
International Journal of Cancer|January 10, 2018
Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohortsWenzhen Ge, Tess V Clendenen, Yelena Afanasyeva, et al.
Breast Cancer Research : BCR|March 21, 2019
Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail modelTess V Clendenen, Wenzhen Ge, Karen L Koenig, et al.
The Journal of Clinical Endocrinology and Metabolism|June 22, 2021
Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal WomenTess V Clendenen, Wenzhen Ge, Karen L Koenig, et al.
British Journal of Cancer|September 6, 2017
Anti-Mullerian hormone and endometrial cancer: a multi-cohort studyRenée T Fortner, Helena Schock, Seungyoun Jung, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancerClaire S Zhu, Paul F Pinsky, Daniel W Cramer, et al.
Fertility and Sterility|April 4, 2017
Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal womenSeungyoun Jung, Naomi Allen, Alan A Arslan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 7, 2011
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal statusSteven J Skates, Phuong Mai, Nora K Horick, et al.
International Journal of Cancer|September 19, 2017
Anti-Müllerian hormone and risk of ovarian cancer in nine cohortsSeungyoun Jung, Naomi Allen, Alan A Arslan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
American Journal of Clinical Pathology|January 30, 2009
Check Sample AbstractsDavid Alter, David G Grenache, David S Bosler, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
International Journal of Cancer|January 10, 2018
Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohortsWenzhen Ge, Tess V Clendenen, Yelena Afanasyeva, et al.
Breast Cancer Research : BCR|March 21, 2019
Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail modelTess V Clendenen, Wenzhen Ge, Karen L Koenig, et al.
The Journal of Clinical Endocrinology and Metabolism|June 22, 2021
Breast Cancer Risk Factors and Circulating Anti-Müllerian Hormone Concentration in Healthy Premenopausal WomenTess V Clendenen, Wenzhen Ge, Karen L Koenig, et al.
British Journal of Cancer|September 6, 2017
Anti-Mullerian hormone and endometrial cancer: a multi-cohort studyRenée T Fortner, Helena Schock, Seungyoun Jung, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancerClaire S Zhu, Paul F Pinsky, Daniel W Cramer, et al.
Fertility and Sterility|April 4, 2017
Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal womenSeungyoun Jung, Naomi Allen, Alan A Arslan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 7, 2011
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal statusSteven J Skates, Phuong Mai, Nora K Horick, et al.
International Journal of Cancer|September 19, 2017
Anti-Müllerian hormone and risk of ovarian cancer in nine cohortsSeungyoun Jung, Naomi Allen, Alan A Arslan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
American Journal of Clinical Pathology|January 30, 2009
Check Sample AbstractsDavid Alter, David G Grenache, David S Bosler, et al.
Pageof 8